Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,093,661
  • Shares Outstanding, K 56,027
  • Annual Sales, $ 638,760 K
  • Annual Income, $ 41,580 K
  • EBIT $ -5 M
  • EBITDA $ 65 M
  • 60-Month Beta 0.96
  • Price/Sales 12.85
  • Price/Cash Flow 48.30
  • Price/Book 4.07

Options Overview Details

View History
  • Implied Volatility 49.04% ( -0.69%)
  • Historical Volatility 63.39%
  • IV Percentile 60%
  • IV Rank 46.31%
  • IV High 68.19% on 11/11/24
  • IV Low 32.53% on 05/17/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 1,065
  • Volume Avg (30-Day) 268
  • Put/Call OI Ratio 1.94
  • Today's Open Interest 8,528
  • Open Int (30-Day) 7,749

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.41
  • Number of Estimates 6
  • High Estimate 0.45
  • Low Estimate 0.35
  • Prior Year 0.33
  • Growth Rate Est. (year over year) +24.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.54 +5.80%
on 11/21/24
161.24 -10.40%
on 12/16/24
+5.56 (+4.00%)
since 11/20/24
3-Month
121.52 +18.88%
on 11/15/24
161.24 -10.40%
on 12/16/24
+1.49 (+1.04%)
since 09/20/24
52-Week
113.50 +27.28%
on 06/20/24
211.13 -31.58%
on 02/16/24
-35.36 (-19.66%)
since 12/20/23

Most Recent Stories

More News
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report

RGEN : 144.46 (-1.42%)
Repligen Corporation Launches AVIPure® dsRNA Clear OPUS® Columns to Enhance mRNA Therapeutics Production

Repligen launches AVIPure dsRNA Clear OPUS columns for improved mRNA therapeutic production, enhancing dsRNA impurity removal efficiency.Quiver AI SummaryRepligen Corporation has launched its AVIPure®...

RGEN : 144.46 (-1.42%)
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

RGEN : 144.46 (-1.42%)
Insider Sale: Director at $RGEN (RGEN) Sells 24,246 Shares

Anthony Hunt, a director at $RGEN ($RGEN), sold 24,246 shares of the company on 11-21-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 14.8% of their shares....

RGEN : 144.46 (-1.42%)
Repligen: Q3 Earnings Snapshot

Repligen: Q3 Earnings Snapshot

RGEN : 144.46 (-1.42%)
Repligen Reports Third Quarter 2024 Financial Results

RGEN : 144.46 (-1.42%)
Repligen Corporation to Present at Upcoming Investor Conferences

RGEN : 144.46 (-1.42%)
Repligen to Report Third Quarter 2024 Financial Results

RGEN : 144.46 (-1.42%)
Here's Why Shares in This Hot Healthcare Stock Surged This Week

The bioprocessing market is preparing for a recovery.

RGEN : 144.46 (-1.42%)
Repligen: Q2 Earnings Snapshot

Repligen: Q2 Earnings Snapshot

RGEN : 144.46 (-1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 155.29
2nd Resistance Point 152.93
1st Resistance Point 148.69
Last Price 144.46
1st Support Level 142.09
2nd Support Level 139.73
3rd Support Level 135.49

See More

52-Week High 211.13
Fibonacci 61.8% 173.84
Fibonacci 50% 162.32
Fibonacci 38.2% 150.79
Last Price 144.46
52-Week Low 113.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar